Non-founder total target cash compensation in 2017 increased 8.3% year-over-year at private life sciences companies and 6.4% at private technology companies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rychlik, B. Nat. Biotechnol. 35, 383–386 (2017).
Rychlik, B. Nat. Biotechnol. 34, 667–670 (2016).
Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton University Press, 2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares competing interests. Cognition Therapeutics is a former client of Park Square Executive Research.
Rights and permissions
About this article
Cite this article
Rychlik, B. As life sciences sector's positive momentum continues, so do executive compensation levels. Nat Biotechnol 36, 661–664 (2018). https://doi.org/10.1038/nbt.4188
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4188